uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.

September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research. 

⏱️7 min read | The CAG repeat that causes HD has a tendency to grow with age. New research on over 900,000 people uncovers parallel patterns and finds CAG growth can happen in many other parts of the genome.